Background {#S1}
==========

The Importance of Cellular Lipid Membranes {#S1.SS1}
------------------------------------------

Cell membranes are composed of several lipid classes and membrane-bound proteins/receptors that interface cellular organelles, and cells with their environment. It is now recognized that these membrane lipids are important in maintaining cellular functions. Several studies show that perturbation of membrane lipids can have devastating consequences on the brain. These changes underlie Alzheimer's disease (AD) pathology depicted in [Figure 1](#F1){ref-type="fig"}. We will examine factors that affect lipid metabolism, describe the functions of brain lipids, and examine the consequences and contributions of lipid dyshomeostasis on AD pathology.

![Factorsthat affect brain lipid metabolism and the importance of lipids in healthy aging and AD. *Factors that affect brain lipid metabolism* -- Demographic factors, genetics, lifestyle, the environment, and trauma can influence lipid metabolism in the brain. Interestingly, these factors that influence lipid metabolism are also recognized risk factors of AD. Abnormalities in lipid metabolism can contribute to dysfunctional brain networks that associate with AD pathology. *Importance of lipid metabolism in brain function and AD pathology* -- In healthy aging, normal transport of lipids through apolipoproteins contribute to the function of the brain. Homeostatic control of the brain lipid environment is responsible for sustaining a normal BBB, providing the right environment for normal APP processing, the right composition for ion channels and receptors, cytosis, vesicle formation, and secretion, signaling, inflammation, oxidation, energy balance, and membrane biosynthesis and remodeling. Dyshomeostasis in lipid delivery into the brain and its metabolism attributes to disturbed BBB, abnormal APP processing, disturbance in cytosis, signaling, energy balance, and enhanced/sustained inflammation and oxidation. Over time, these processes lead to neuronal death that is the hallmark of AD pathology.](fphys-11-00598-g001){#F1}

Brain Lipids in Healthy Aging and AD Pathology {#S1.SS2}
----------------------------------------------

Most of the brain is composed of lipids, which can be grouped as sphingolipids, glycerophospholipids, and cholesterol ([@B420]; [@B329]; [@B237]). The brain consists of straight-chain monocarboxylic acids ranging from C~12~ to C~26~, and omega-3 (n-3) and omega-6 (n-6) fatty acids are most abundant ([@B237]; [@B391]). Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are prominent polyunsaturated fatty acids (PUFA) in the brain that are derived from alpha-linolenic acid (ALA), an omega-3 fatty acid ([@B73]). Arachidonic acid (AA) and docosatetraenoic acid (DPA) constitute a large proportion of PUFA's that are derived from linolenic acid (LNA), an omega 6 fatty acid ([@B253]; [@B395]).

Factors That Affect Brain Lipids {#S2}
================================

Demographic Factors That Influence Brain Lipids {#S2.SS1}
-----------------------------------------------

### Brain Lipids Changes in Aging {#S2.SS1.SSS1}

These PUFA's are incorporated into membrane phospholipids and therefore play a significant role in structural integrity and function of cell membranes. Lipid metabolism is changed during aging ([@B306]; [@B482]; [@B460]; [@B104]; [@B93]; [@B73]), as shown by a decline in omega-3 fatty acids and an increase in lipid peroxidation ([@B76]). Omega-3 fatty acids have antioxidant properties, and a lack of these fatty acids in one's diet may accelerate neuronal degeneration ([@B482]; [@B216]). Susceptibility of lipids to peroxidation increases with age ([@B51]; [@B405]; [@B104]; [@B76]), which supports using the level of oxidative stress as a critical determinant of neuronal health and longevity ([@B202]). Previous studies have suggested that DHA and EPA may protect against peroxidation and the effects of age-related brain pathology ([@B181]; [@B76]). Lipids are involved in cellular signaling, energy balance, blood-brain barrier (BBB), and inflammation ([@B402]; [@B464]), and such age-dependent lipidome changes that disrupt these functions may contribute to neurodegenerative diseases ([@B16]; [@B50]; [@B196]; [@B273]; [@B292]; [@B255]), such as Alzheimer's disease (AD) ([@B370]; [@B203]).

### Lipids and Race/Ethnicity {#S2.SS1.SSS2}

Race and ethnicity play a significant role in the risk of AD and related disorders. In 2014, nearly 5 million people over the age of 65 had been diagnosed with Alzheimer's disease or related dementias (ADRD) ([@B285]). African Americans and Hispanics had the highest prevalence of ADRD (13.8% and 12.2%, respectively), while ADRD was least common in Asian and Pacific Islanders (8.4%), followed by American Indian/Alaska Natives (9.1%), non-Hispanic whites (10.3%), and people with two or more races (11.5%) ([@B285]). Ethnic and racial backgrounds impact many aspects of health, including diet, stress, access to medical treatment, and biological factors of disease. From past research, we can clearly see the ways in which ethnicity, race, and lipids overlap. Most clearly seen in the high incidence of both dyslipidemia, or abnormal amounts of lipids in the blood, and cardiovascular disease observed in minority populations ([@B144]), race/ethnic disparities affect the regulation of lipid metabolism. Increased concentrations of triglycerides (TG) and decreased levels of lipid carriers, such as HDL-C (high-density lipoprotein-cholesterol) in the blood of Mexican, Filipino, Indian, and Vietnamese people compared to whites may provide a possible explanation for higher risk of both ADRD and cardiovascular disease within these populations ([@B144]; [@B152]). HDL-C is often referred to as "good cholesterol," has beneficial antioxidant and anti-inflammatory effects in the body, and has been observed to modulate ß-amyloid (Aß) production in the brain, a key biomarker of AD pathogenesis ([@B360]; [@B198]). Lowered levels of HDL-C have been associated with increased cognitive decline and poor cardiovascular health outcomes ([@B198]). TG, which is increased in almost every minority population, except African Americans, has been shown to relate to central leptin- and insulin resistance in the brain and decreases in cognition ([@B417]; [@B144]; [@B24]). In light of the less marked changes in lipid make-up and metabolism seen in African American populations at increased risk of ADRD, it has been suggested that African Americans are underdiagnosed with metabolic syndromes and vascular-cognitive disorders ([@B417]). Furthermore, it has been observed that there is a differential expression of various molecular biomarkers of AD (phosphorylated tau and total tau) in African Americans compared to whites ([@B308]), suggesting even small, imperceptible changes in lipid distribution in this population may be sufficient to affect cognition negatively. It is important to note that despite the disproportionate impact ADRD has on minority populations, these individuals continue to be considerably underrepresented in ADRD research, contributing to large gaps in our understanding of brain lipid metabolism as it pertains to race and ethnicity ([@B155]).

### Lipids and Sex {#S2.SS1.SSS3}

Sex continues to be one of the largest risk factors for developing AD. Females not only makeup two-thirds of all cases of AD diagnoses but also possess a greater lifetime risk of dementia compared to men due to longer life expectancy ([@B446]; [@B298]). Increased prevalence and risk of AD and other age-related disorders among females have been attributed to not only extended life expectancy but also to sudden decreases in estrogen post-menopause, among many other factors including education level and mental health status ([@B446]; [@B298]). Despite the many factors that may contribute to increased risk of AD in women, the contribution of sex-hormone levels and differential lipid distribution play evident roles in cognitive decline are not fully understood. Not only is fat in the form of TG distributed differently in the adipose tissue of male and females, which can be attributed in part to sex-hormone signaling, but concentrations of long-chain PUFAs (LC-PUFAs) have also been observed to be increased in women pre-menopause compared to men ([@B101]; [@B268]). Correspondingly, a positive association has been established between omega-3 LC-PUFA biosynthesis, i.e., the production of EPA and DHA, and circulating concentrations of estrogen and progesterone ([@B81]). Estrogen, an ovarian steroid hormone, is hypothesized to affect lipid metabolism at several points during biosynthesis, including playing a key role in lipid transport and exchange, increasing expression of metabolic enzymes, and reducing the oxidation of α-linoleic acid (ALA), the deriving fatty acid in n-3 LC-PUFA production ([@B81]; [@B101]; [@B268]; [@B335]). Estrogen has also been directly associated with inhibiting memory function impairment in premenopausal women following the surgical removal of their ovaries and loss of the ability to produce estrogen endogenously ([@B115]; [@B381]). In a study of *trans*-sexual subjects, those transitioning from male to female and receiving estrogen observed an increase in DHA plasma levels while those transitioning from female to male and receiving testosterone treatment experienced a marked decrease in plasma DHA ([@B156]). The decrease in estrogen levels, as seen in post-menopausal women, has also been associated with increased TG content and lower HDL-C, both of which have been linked to cognitive decline ([@B105]; [@B9]). This is to say, the increased prevalence and risk for AD among women can be explained in part by the abrupt decrease in estrogen production that accompanies the post-menopausal state. Not only does the lack of estrogen decrease concentrations of anti-inflammatory LC-PUFAs and HDL-C in the body, but it also increases TG levels, augmenting secretion of VLDL (very-low density lipoprotein), a lipid carrier known to induce neuroinflammation ([@B58]; [@B78]; [@B315]). Additionally, genetic factors, such as ApoE status, and social determinants, such as education, mental illness, and diet, interact with the post-menopausal state to amplify these detrimental effects, increasing risk of AD.

Lipids and Lifestyle {#S2.SS2}
--------------------

### Diet {#S2.SS2.SSS1}

Dietary lipids play an integral part in physiological lipid metabolism and, consequently, in the risk of AD and cardiovascular disease. Essential fatty acids like DHA (n-3) and AA (n-6) are largely derived from the dietary consumption of their shorter-chained, slightly less-saturated counterparts ALA (n-3) and LA (n-6), respectively ([@B372]; [@B309]). After consumption of these deriving fatty acids, the body is able to anabolize them, creating the LC-PUFAs that contribute to neural processes ([@B309]). Early on in human existence, our diet consisted of an equal balance of n-6 to n-3 essential fatty acids, but as we have evolved, the n-3 to the n-6 ratio of dietary fatty acids has greatly shifted to one side ([@B394]). Today, the Western diet has a ratio of about 17 to 1 n-6 to n-3 fatty acids, meaning most Americans have a lot more LA, AA, and DPA in their bodies, which are able to produce relatively large quantities of inflammatory and oxidative mediators ([@B394]). Increased ratios of n-6 to n-3 dietary fatty acids have also been directly associated with increased cognitive decline and risk of AD ([@B266]; [@B274]). DHA, on the other hand, an n-3 LC-PUFA usually found in fish and algae, is not largely found in the Western diet. Studies suggest, however, that DHA supplementation may work to combat neuroinflammation, oxidative stress, and cognitive decline. Fish oil supplements containing large amounts of DHA, given to older adults with varying levels of cognition, found that supplementation resulted in decreased brain atrophy and less cognitive decline compared to controls in an *APOE* allele-dependent manner ([@B94]). Similarly, Morris et al. observed among subjects over the age of 65 that those who ate fish at least once a week had 60% less risk of AD than those who rarely or never ate fish ([@B310]). Dietary DHA has also been shown to improve cognition, memory, and brain development from the earliest stages of life through adulthood ([@B116]; [@B291]; [@B313]; [@B413]; [@B456]).

It is important to note that diet can be particularly impacted by race/ethnicity, as well as physical geography, helping to explain differences in AD risk among ethnic groups. According to a global survey of 298 studies, highest levels of DHA and EPA, another n-3 fatty acid, were observed among Japanese, Scandanavian, and indigenous populations, as well as in areas where the Westernized diet had not been fully adopted ([@B409]). Authors of this survey argue increased consumption of seafood, as dictated by culture or geographical location, greatly impact n-3 LC-PUFA levels in the bloodstream, which offer protective cognitive effects at every stage in life ([@B218]; [@B409]; [@B456]).

Genetical Evidence for the Importance of Lipid Metabolism in AD Pathology {#S2.SS3}
-------------------------------------------------------------------------

### Genetic Risk Factors of AD-Related to Lipid Metabolism {#S2.SS3.SSS1}

Genome-wide Association Studies GWAS and Transcriptome-Wide Association Studies (TWAS) associate AD pathology with several lipid genes ([@B382]; [@B176]). While the APOE4 allele carries the greatest risk for AD, other genes and gene-products commonly associated with AD pathology are linked to or interact with lipid metabolism. Several lipid genes associated with AD pathology have recently been reviewed ([@B427]). [Table 1](#T1){ref-type="table"} is the list of the major genes from GWAS that are linked with lipid metabolism ([@B220]).

###### 

Lipid metabolism-associated genes with SNP (\<0.001) linked with AD from GWAS.

  Gene Symbol \[*Chromosome location* (*Mb*)\] ([@B220])   The function of the gene product^\#^                                                                                                                                                                                                                                                                                                                                     Changes and known effects on AD pathology
  -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  APOE \[*19* (*50*)\]                                     As part of lipoproteins, ApoE is involved in the transport and distribution of lipids into various tissues via plasma and other interstitial fluids ([@B200])                                                                                                                                                                                                            Polymorphism of APOE is associated with age of onset ([@B111]; [@B444]), cognitive and memory decline ([@B17]; [@B120]), amyloid load ([@B293]), cholesterol homeostasis ([@B251]), inflammation ([@B436])
  APOC1 \[*19* (*50*)\]                                    Involved in HDL and VLDL metabolism, inhibitor cholesteryl ester transfer protein in plasma                                                                                                                                                                                                                                                                              Gene polymorphism ([@B351]), oxidative stress ([@B351]), interaction with ApoE ([@B272]), cognitive impairment ([@B498])
  CLU \[*8* (*28*)\]                                       Clusterin (ApoJ) is a component of lipoproteins associated with lipids in plasma and CSF                                                                                                                                                                                                                                                                                 Polymorphism ([@B390]; [@B500]), interaction with PICALM ([@B178]; [@B226]), hippocampal function ([@B122]).
  APOC2 \[*19* (*50*)\]                                    A component of triglyceride (TG)-rich lipoproteins, including VLDL, HDL), and chylomicrons involved metabolism of these particles; promote VLDL1 secretion, inhibit lipoprotein lipase enzyme activity                                                                                                                                                                   Polymorphism associated with AD ([@B419]), decreased expression associated with increased risk ([@B261])
  APOC4 \[*19* (*50*)\]                                    A lipid-binding lipoprotein thought to play a role in lipid metabolism                                                                                                                                                                                                                                                                                                   Decreased expression associated with increased risk ([@B261])
  ABCA7 \[*19* (*1*)\]                                     Member of the ATP-binding cassette (ABC) superfamily of transporters; catalyzes the translocation of specific phospholipids from the cytoplasmic to the extracellular/lumenal leaflet of the membrane coupled with ATP hydrolysis, lipid homeostasis, binds APOA1, apolipoprotein-mediated phospholipid efflux from cells, cholesterol efflux, lipid raft organization   Polymorphism correlate with memory impairment ([@B72]), amyloid plaque burden ([@B493]), cognitive impairment ([@B88]; [@B38])
  ABCA1 \[*9* (*107*)\]                                    A membrane of the superfamily of ATP-binding cassette (ABC) transporters with cholesterol as its substrate, it functions as a cholesterol efflux pump in the cellular lipid removal pathway                                                                                                                                                                              Polymorphism in AD ([@B86]; [@B455]; [@B454]), modulates cholesterol efflux ([@B384]; [@B235]; [@B279]), influences age of onset ([@B468])
  ABCA12 \[*2* (*216*)\]                                   A membrane of the superfamily of ATP-binding cassette (ABC) transporters involved in the transport of molecules across the cellular membrane                                                                                                                                                                                                                             SNP with *p* \< 0.001 and significantly enriched in AD ([@B220])
  LIPC \[*15* (*57*)\]                                     Hepatic triglyceride lipase is a triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake                                                                                                                                                                                                                                              Gene variant might influence AD susceptibility ([@B475])
  ATP8A1 \[*4* (*42*)\]                                    ATPase Phospholipid Transporting 8A1 catalyzes ATP hydrolysis that is coupled to the transport of aminophospholipids from the outer to the inner leaflet of membranes to maintain their asymmetric distribution                                                                                                                                                          SNP with *p* \< 0.001 and significantly enriched in AD ([@B220])
  ATP8B4 \[*15* (*48*)\]                                   Amninophospholipid transport across cell membranes                                                                                                                                                                                                                                                                                                                       SNP with *p* \< 0.001 and significantly enriched in AD ([@B220])
  MALL \[*2* (*110*)\]                                     Member of the MAL proteolipid family localizes in glycolipid- and cholesterol-enriched membrane (GEM) rafts, and interacts with caveolin-1                                                                                                                                                                                                                               SNP with *p* \< 0.001 and significantly enriched in AD ([@B220])
  ATP8A2 \[*13* (*25*)\]                                   Involved in flipping phospholipids from the exoplasmic leaflet to the cytosolic leaflet of the cell membrane to generate or maintain membrane lipid asymmetry                                                                                                                                                                                                            SNP with *p* \< 0.001 and significantly enriched in AD ([@B220])
  OSBPL7 \[*17* (*43*)\] OSBPL9 \[*1* (*59*)\]             Oxysterol-binding protein (OSBP) family, intracellular lipid receptors Oxysterol-binding protein (OSBP) family, a group of intracellular lipid receptors; cholesterol transfer protein and regulation of Golgi structure and function                                                                                                                                    Differential expression ([@B56]; [@B188])
  SCARB1 \[*12* (*124*)\]                                  Scavenger Receptor Class B Member 1 is a plasma membrane receptor for HDL that also mediates cholesterol transfer to or from HDL                                                                                                                                                                                                                                         Cholesterol efflux and anti-inflammation ([@B235]), endocytosis, transcytosis and Abeta removal ([@B275]; [@B407])
  VPS4B \[*18* (*59*)\]                                    Vacuolar Protein Sorting 4 Homolog B involved in late endosomal multivesicular bodies (MVB) pathway. Degradation of lysosomal enzymes and lipids.                                                                                                                                                                                                                        SNP with *p* \< 0.001 and significantly enriched in AD ([@B220])
  ABCG1 \[*21* (*42*)\]                                    Coupled to ATP hydrolysis, catalyzes the efflux of sphingomyelin, cholesterol, and oxygenated derivatives like 7-beta-hydroxycholesterol.                                                                                                                                                                                                                                Cholesterol efflux ([@B193]; [@B467]; [@B279])
  LIPG \[*18* (*43*)\]                                     Diverse class of lipase enzymes includes diacylglycerol lipase (DAGL) and lipoprotein lipase (LPL) and endothelial lipase (LIPG). Hydrolyzes HDL more efficiently than other lipoproteins                                                                                                                                                                                Polymorphism and mutation ([@B30]; [@B47]), cholesterol homeostasis ([@B46]; [@B133]), stimulation in nucleus basalis and hippocampus ([@B129])
  PCTP \[*17* (*51*)\]                                     Phosphatidylcholine (PC) Transfer Protein; PC synthesis and metabolism, binds single PC molecule and transfers between membranes                                                                                                                                                                                                                                         Cholesterol transport ([@B239]; [@B103])
  SLC27A4 \[*9* (*130*)\]                                  Family of fatty acid transport proteins; translocation of long-chain fatty acids across the plasma membrane, has acyl-CoA ligase activity for long-chain and very-long-chain fatty acids (VLCFAs)                                                                                                                                                                        SNP with *p* \< 0.001 and significantly enriched in AD ([@B220])
  NPC1 \[*18* (*19*)\]                                     Intracellular cholesterol transporter which is important in cholesterol removal from endosomal/lysosomal compartment                                                                                                                                                                                                                                                     Increase expression ([@B223]; [@B287]), neurocognitive deficit ([@B219])
  APOA1 \[*11* (*116*)\]                                   Apolipoprotein A-I is the major protein HDL in plasma. It promotes cholesterol efflux from tissues to the liver for excretion and is a cofactor for lecithin cholesterol acyltransferase (LCAT), an enzyme that forms cholesteryl ester                                                                                                                                  Polymorphism and decreased expression ([@B185]; [@B398]; [@B385]; [@B261])
  APOC3 \[*11* (*116*)\]                                   A component of triglyceride-rich VLDL, and HDL in plasma. Important in triglyceride homeostasis: promotes hepatic VLDL1 assembly and secretion, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins, impairs TRL lipolysis by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors                                        Polymorphism and decreased expression ([@B261]; [@B419])
  APOA4 *\[11 (116*)\]                                     Apolipoprotein A4 is a major component of HDL and chylomicrons. Important in chylomicrons and VLDL secretion and catabolism. Required for lipoprotein lipase activation by ApoC-II, a potent activator of LCAT                                                                                                                                                           Decreased expression ([@B261]), enhanced susceptibility ([@B340])
  AGTR1 \[*3* (*1490*)\]                                   Angiotensin II is a primary regulator of aldosterone secretion                                                                                                                                                                                                                                                                                                           Signal transduction abnormality ([@B339])
  SOAT1 \[*1* (*177*)\]                                    Sterol O-Acyltransferase-1 is an acyltransferase that catalyzes the formation of fatty acid and cholesterol esters, which is important in lipoprotein assembly and dietary cholesterol absorption. It may also act as a ligase                                                                                                                                           Polymorphism ([@B249]), Cholesterol levels, amyloid load ([@B469])

\#

https://www.genecards.org/

.

Genome-wide Association Studies suggest that age-related changes in brain lipid metabolism may be essential to healthy aging and longevity ([@B427]). Identification of AD-related genes and how these interact with specific risk factors may provide the rationale for designing effective therapies.

The onset of age related disease can be accelerated with suppression of anti-aging genes, such as Sirtuin 1 (SIRT1). SIRT1 is a histone deacetylase involved with gene expression related to metabolic activity ([@B163]). SIRT1 interacts with lipid metabolism regulation and hepatic oxidative stress and inflammation ([@B110]). It also regulates circadian rhythms in the liver and brain, maintaining the body's regulation of glucogenesis, fatty acid beta-oxidation, and cholesterol biosynthesis ([@B35]). Its involvement in metabolism explains its effects on energy metabolism, neurogenesis, glucose and cholesterol metabolism, and amyloidosis. Sirt 1 also contributes to neuron apoptosis and survival. Downregulation of this anti-aging gene may lead to acceleration of neurodegenerative disease. Nutritional interventions, such as a reduction in overconsumption of carbohydrates, are recommended because they may be associated with preventing cell senescence and maintaining anti-aging gene activity ([@B284]). SIRT1 expression promotes APP processing on a non-amyloidogenic pathway and clearance of tau from the brain ([@B189]). SIRT1's deacetylase activity increases the activity of lysosome-related genes, facilitating Aβ degradation ([@B258]). SIRT1 is a potential therapeutic target for AD because of its involvement in many amyloid beta and cholesterol pathways.

Contribution of Lipids to AD Pathology {#S3}
======================================

Although the brain has a very high concentration of long-chain omega-3 and omega-6 fatty acids, there is no conclusive explanation for how these fatty acids participate in various signaling cascades and in AD ([@B431]; [@B303]). However, lipodomic studies related to AD pathology have demonstrated a decrease in DHA levels within the brain, predominantly in the hippocampus ([@B34]). Damage to the hippocampus is associated with impaired learning and memory abilities, a symptom of AD onset ([@B368]). With growing evidence that AD is associated with dysregulation of fatty acid metabolism, fatty acid levels may be potential biomarkers of this disease ([@B141]; [@B472]). In addition to omega fatty acids, the levels of several lipids change with AD pathology ([Table 2](#T2){ref-type="table"}).

###### 

Summary of lipids that change in AD.

  Lipids                                                                           Changes observed in AD
  -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Fatty acids**                                                                  
  Omega-3 fatty acids (^\#^DHA, EPA, DPA, ALA)                                     DHA decreased in brains, circulation, and CSF of AD individuals ([@B141], [@B140]; [@B100]; [@B399]; [@B197]). EPA decreased in brain and circulation of AD individuals ([@B197]). DPA increased in livers of AD ([@B117]). ALA increased in plasma and peripheral tissues ([@B80]).
  Omega-6 fatty acids (^\#^AA, LA)                                                 AA increased in brains, erythrocytes, and CSF of AD individuals ([@B426]; [@B162]; [@B140]). LA decreased in AD brain and plasma ([@B399]; [@B92]).
  Saturated fatty acids (^\#^PA, SA, C15:0)                                        Increased in the CSF and brains of AD individuals ([@B141]). Odd chain saturated fatty acids derived from microbiome or measures of dairy consumption decreased in CSF of AD ([@B141]; [@B316]).
  Eicosanoids                                                                      Pro-inflammatory eicosanoid pathways are upregulated in AD individuals, while anti-inflammatory eicosanoids are decreased ([@B44]). Prostaglandin and thromboxane B~2~ increased in AD brains ([@B212]). Pro-resolvin mediators, such as lipoxins, are reduced in AD brains ([@B453]).
  Endocannabinoids                                                                 Decreased levels of endocannabinoids and receptors in AD brains ([@B32]).
  **Glycerolipids**                                                                
  Triglycerides                                                                    Total TG lipid levels decreased in the serum of individuals with probable AD ([@B254]). Polyunsaturated TG decreased in AD brains ([@B39]).
  **Glycerophospholipids**                                                         
  Phosphatidylcholine (PC) Phosphatidylethanolamine (PE) Phosphatidylserine (PS)   Total PC lipids decreased in AD brains ([@B473]). PC species decreased in CSF of AD individuals **^\#^***PC32:0, PC34p:0/34e:1, PC34:1, PC34:0, PC36:1, PC38a:5 (PC-EPA), PC36:0/38p:6, 38a:6 (PC-DHA)* ([@B139]). PC species decreased in plasma of AD individuals. *PC36:5 (PC-EPA), PC38:6 (PC-DHA), PC40:6 (PC-DHA)* ([@B461]). PC species increased in the prefrontal cortex of AD individuals. *PC38:6 (PC-DHA)*, *PC40:6 (PC-DHA)* ([@B205]). Total PE lipids decreased in the hippocampus of AD individuals ([@B350]). PE species decreased in the hippocampus of AD individuals. *PE-SA*, *PE-OA*, *PE-AA*, *PE-DHA* ([@B168]). A decrease in PE plasmalogen in AD ([@B128]). Total PS lipids decreased in the occipital lobe and inferior parietal lobule of AD brains ([@B128]).
  **Sphingolipids**                                                                
  Sphingomyelin (SM) Ceramides (CM) Sulfatides Gangliosides                        Total SM lipids lower in CSF of AD individuals ([@B142]). SM species decreased in the CSF of AD individuals **^\#^***SM18/14:0, SM18/16:0, SM18/16:1, SM18/17:0* SM species *(SM18/18:0, SM18/18:1)* increased in the CSF of prodromal AD individuals ([@B244]). Total CM lipids increased in AD brains ([@B134]). CM species increased in AD brains and plasma *CM16:0 (PA), CM18:0 (SA), CM20:0, CM24:0, CM24:1* ([@B236]). Total sulfatide levels significantly lower in AD brains in both gray and white matter. The compositional distribution of sulfatide subtypes is unaltered ([@B173]). Ganglioside lipid levels reduced in the temporal lobe of AD brains ([@B304]).
  **Sterols**                                                                      
  Cholesterol Oxysterols Hormones                                                  Cholesterol decreased, and oxysterol/cholesterol precursors increased in MCI and sporadic AD brains ([@B182]). Total oxidized cholesterol increased in AD brains ([@B191]). Oxidized cholesterol species decreased in AD brains, *24S-hydroxycholesterol* ([@B191]). Oxidized cholesterol species increased in AD brains, *27-hydroxycholesterol* ([@B191]). Lower estrogen increases the risk of AD ([@B359]; [@B437]). Increased basal cortisol levels in the plasma of demented individuals ([@B91]). Association of cortisol with Aβ deposition ([@B429]) and with hypometabolism ([@B465]).

\#

DHA, Docosahexaenoic acid (C22:6, n-3); EPA, Eicosapentaenoic acid (C20:5, n-3); DPA, Docosapentaenoic acid (C22:5, n-3); ALA, Alpha-linolenic acid (C18:3, n-3); AA, Arachidonic acid (C20:4, n-6); LA, Linoleic acid (C18:2, n-6); PA, Palmitic acid (C16:0); SA, Stearic acid (C18:0); OA, Oleic Acid (C18:1, n-9); PC, phosphatidylcholine; PCxxa:\#, PC specie with xx carbon number and acyl-linked fatty acid at the sn-1 position containing \# (number) double bonds; PC

xx
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, PC specie with xx carbon number and alk-1-enyl (plasmalogen)-linked fatty acid at the sn-1 position containing \# (number) double bonds PC

xx

e:
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PC specie with xx carbon number and alkyl (ether)-linked fatty acid at the sn-1 position containing \# (number) double bond; PE, phosphatidylethanolamine; PS, phosphatidylserine; SM, sphingomyelin; CM, ceramide; TG, triglyceride.

Lipid Transport: Apolipoproteins {#S3.SS1}
--------------------------------

### Brain Lipoproteins and Their Function {#S3.SS1.SSS1}

Lipoproteins are molecules with a hydrophobic lipid core composed of cholesterol, esters, and triglycerides and a hydrophilic exterior of phospholipids, apolipoproteins, and free cholesterol ([@B4]; [@B195]; [@B54]). Lipoproteins assist with the transport of lipids and amphipathic compounds throughout the body ([@B130]). However, circulating plasma lipoproteins differ from those within the CNS because only high-density lipoproteins (HDL) can cross the blood-brain barrier ([@B21]). The most abundant apolipoproteins, apolipoprotein E (ApoE), and apolipoprotein J (ApoJ) are synthesized by astrocytes and serve as enzyme cofactors and receptor ligands on HDL ([@B349]; [@B130]; [@B211]).

Apolipoproteins are greatly involved in metabolism, serving as both activators and inhibitors of metabolic enzymes, ligands for lipoprotein receptors, and providing structural support ([@B130]; [@B49]; [@B135]). They also regulate lipid transport by controlling interactions with receptors, enzymes, and lipid-transport proteins ([@B49]; [@B357]). Apolipoproteins have receptor binding domains containing low-density lipoprotein (LDL) receptors that direct lipid and substrate delivery to specific brain cells ([@B90]; [@B102]; [@B190]). Their amphipathic-helices facilitate lipid-binding and lipid transport ([@B90]; [@B353]; [@B121]). LDL receptors also facilitate the clearance of amyloid peptides through the BBB ([@B383]).

### Contribution of Lipoproteins to AD Pathology {#S3.SS1.SSS2}

Brain lipoproteins with ApoE are responsible for phospholipid and cholesterol transport ([@B167]; [@B471]). ApoE is mainly expressed in astrocytes and microglia and appears as three major isoforms, ApoE2, ApoE3, and ApoE4, of which ApoE4 is the strongest genetic risk factor for AD ([@B412]; [@B210]; [@B441]; [@B89]; [@B265]; [@B307]; [@B434]). ApoE4 demonstrates a lower affinity for lipids than ApoE2 and ApoE3, limiting CNS transport of lipids needed for neuronal remodeling and repair ([@B53]; [@B25]; [@B259]; [@B151]). Furthermore, levels of ApoE LDL receptors directly correlate with Aβ clearance, and promoting the expression of these receptors are potential therapeutic targets for AD treatment ([@B492]). ApoJ, also known as clusterin, is expressed in astrocytes, neurons, and ependymal cells ([@B327], [@B326]). This neuroprotectant initiates a defense response to neuronal damage and clears Aβ across the BBB via LDLR-2 ([@B296]; [@B320]; [@B487]). ApoJ's role in Aβ accumulation and toxicity is still undetermined because variability under different contexts and environments confound results ([@B143]).

Lipids and the Blood-Brain Barrier {#S3.SS2}
----------------------------------

### The Blood-Brain Barrier {#S3.SS2.SSS1}

The blood-brain barrier (BBB) is a semipermeable membrane that carefully regulates the exchange of solutes between blood and brain to maintain CNS homeostasis and block entry of toxins and pathogens into the CNS ([@B52]; [@B2]; [@B40]; [@B95]; [@B131]; [@B311]). The integrity of the BBB is largely dependent on its tight junctions ([@B57]; [@B69]), adherens junction proteins, and ability to control the vesicular movement of macromolecules through transcytosis and pinocytosis ([@B102]; [@B22]). The BBB permits free diffusion of gases, such as oxygen and carbon dioxide, but small solutes such as lipophilic molecules and ions enter through receptor-mediated transcytosis or via channels ([@B137]; [@B501]; [@B352]; [@B12]; [@B445]; [@B19]). The BBB is critical in linking multiple major organ systems, and any dysfunction in the lipid bilayer's ability to act as a barrier may lead to neuronal degeneration ([@B496]; [@B171]; [@B314]; [@B318]).

### Importance of Lipids in BBB Function {#S3.SS2.SSS2}

In addition to composing the BBB lipid bilayer, lipids, including phospholipids, sphingolipids, and cholesterol, also compose the plasma membrane of vesicles involved with receptor-mediated transcytosis within the CNS ([@B246]; [@B112]; [@B63]; [@B12]). The formation and function of vesicles required to transport essential macromolecules across the BBB may be affected by the plasma membrane lipid composition ([@B263]; [@B262]; [@B224]). In particular, DHA disrupts the membrane domains necessary to form such transport vesicles and therefore contributes to BBB integrity and suppression of transcytosis ([@B333]; [@B148]; [@B337], [@B338]; [@B33]). There is also recent evidence that the membrane transport protein, Mfsd2a, controls lipid exchange and plays a key role in the transport of DHA into the brain, though this pathway is largely undetermined ([@B377]; [@B495]; [@B232]; [@B12]). Loss of Msfd2a transport function resulted in decreased DHA transport and increased activity levels of transcytosis within CNS endothelial cells ([@B12]). A leaky barrier increases the brain's susceptibility to toxins and pathogens and homeostasis disruption, and ultimately, neuronal dysfunction ([@B1]; [@B204]; [@B207]; [@B48]).

### The Contribution of the BBB to AD Pathology {#S3.SS2.SSS3}

Loss of BBB function may contribute to neurodegenerative diseases, including AD ([@B23]; [@B154]; [@B501]; [@B68]; [@B230]; [@B421]; [@B231]). According to multiple independent studies, BBB breakdown in AD is demonstrated by decreased integrity of BBB tight junctions, pericyte and endothelial degeneration, RBC extravasation, and brain capillary leakages ([@B501]; [@B68]; [@B99]; [@B321]; [@B421]). A buildup of blood proteins and macromolecules due to barrier leakiness may damage vasculature and brain parenchyma, which induces neuronal degeneration. Studies have also indicated that AD pathology includes reduced expression of glucose transporters in the BBB ([@B225]; [@B177]; [@B169]; [@B3]; [@B48]). This may exacerbate AD cerebrovascular degeneration and cognitive function, considering that the brain requires a continuous supply of glucose and utilizes the most glucose of the major organs ([@B37]; [@B108]; [@B36]; [@B161]). The BBB contains a wide variety of structural components to regulate the brain's health and function, but a loss of function in any such component may lead to dyshomeostasis and a rapid cascade of dysfunctions in other structures within the brain.

Lipids Contribute to Amyloid Precursor Protein Processing {#S3.SS3}
---------------------------------------------------------

### Amyloid Precursor Protein Processing {#S3.SS3.SSS1}

Amyloid precursor protein (APP) is a type I transmembrane protein that is cleaved into amyloid β-peptide (Aβ) by β- and γ-secretases ([@B324]; [@B180]). APP is synthesized in the endoplasmic reticulum and is found in the highest concentrations in neuron's *trans*-Golgi-network, suggesting that APP is associated with secretory pathways ([@B334]; [@B411]; [@B238]; [@B422]; [@B428]; [@B264]). There are two accepted proteolytic pathways for APP processing − non-amyloidogenic and amyloidogenic ([@B209]; [@B243]; [@B396]; [@B362]; [@B300]; [@B404]; [@B208]; [@B403]; [@B84]; [@B450]; [@B430]). The non-amyloidogenic pathway involves cleavage of APP by α-secretase at the plasma membrane, releasing soluble APPα (sAPPα) fragments into the extracellular environment, and normalizes AG genes and memory ([@B448]). The amyloidogenic pathway involves cleavage of APP by β-secretase in early endosomes, releasing sAPPβ fragments in the endosomal lumen, and increasing susceptibility to Aβ plaques that are relevant to AD pathology ([@B123]; [@B160]; [@B366]; [@B119]; [@B13]; [@B165]).

### The Role of Lipids in APP Processing {#S3.SS3.SSS2}

The β-site APP-cleaving enzyme 1 (BACE-1) is the major β-secretase that targets endosomes with APP in transit to endocytosis sites on the plasma membrane ([@B387]; [@B330]; [@B87]; [@B18]). Both APP and BACE-1 are associated with lipid rafts, which are membrane domains enriched with cholesterol, sphingolipids, and gangliosides that are crucial to vesicle trafficking and intracellular transport ([@B119]; [@B484]; [@B280]; [@B41]). Recent studies have proposed that BACE-1 in cholesterol depleted environments displayed inhibited β-secretase activity, suggesting that cholesterol and lipid composition of the intracellular environment may be a large determinant of whether BACE-1 can access APP endosomes ([@B96]; [@B79]; [@B312]). However, other studies suggest that both homeostasis of lipid composition and oxidation state of lipids, including DHA, are critical to APP processing ([@B166]; [@B41]; [Figure 2](#F2){ref-type="fig"}). Under conditions with high concentrations of oxidized lipids, levels of sAPPα fragments decreased while sAPPβ levels increased ([@B165]). A novel mechanism of proteolytic activity regulation of secretases involves a separating lipid boundary with their substrates, APP ([@B222]). Lipid mediators of inflammation also interact with APP processing at the level of O-GlcNAcylation ([@B369]; [@B217]). Thus, oxidized or inflammatory lipids may shift APP processing from the non-amyloidogenic to an amyloidogenic pathway ([Figure 2](#F2){ref-type="fig"}).

![The importance of Lipids on APP processing -- APP is a transmembrane protein that is cleaved by several proteases: α-secretase, β-secretases, and γ-secretases. *Non-amyloidogenic processing of APP*− In a cell with a membrane containing normal or high amounts of unsaturated fatty acids, especially DHA, preference is given to cleavage by α-secretase In this case, a well-structured membrane holds onto an intact APP as it is cleaved by the α-secretase and subsequently the α-secretase releasing the secreted ectodomain sAPPα, along with a small protein fragment, p3, and APP intracellular C-terminal domain (AICD) peptide in the extracellular space. sAPPα and p3 do not form neurotoxic fibrils and plaques, and so this process is referred to as non-amyloidogenic APP processing. *Amyloidogenic processing of APP* -- In contrast, PUFA enriched structure of healthy neurons, the presence of saturated and oxidized fatty acids results in the disruption of the cell membrane structure, and this favors β-secretase activation. APP is cleaved at its' N-terminus by β-secretase, releasing a soluble ectodomain sAPPβ into the extracellular space. γ-secretase subsequently cleaves the cell-associated C-terminus releasing and Aβ peptides of varying lengths into the extracellular space. Insoluble Aβ fibrils aggregate as oligomers that ultimately clump to form plaques within the brain. These plaques contribute to oxidative stress, neuroinflammation, and eventually decreased brain function.](fphys-11-00598-g002){#F2}

### The Intersection of Lipids, APP Processing, and AD Pathology {#S3.SS3.SSS3}

The Aβ fragments of APP is the major component of AD amyloid plaques, and such dysregulation of APP trafficking and processing are relevant to understanding AD pathology ([@B66]; [@B425]; [@B490]; [@B423]; [@B486]). Intracellular Aβ accumulation in neurons of patients with AD and metabolic analysis of brain function indicate a possible dysfunction in Aβ transport exiting the brain ([@B330]; [@B486]). Lipids rafts play important roles in APP trafficking ([@B484]; [@B476]). Moreover, palmitoylation dictates how APP is processed ([@B41]). *Trans* fatty acids influence amylogenic APP processing, while the level of fatty acid unsaturation determines the activity of secretases ([@B478]; [@B166]). Future research relating to changes in brain lipid composition in pre-symptomatic AD may provide a link with early disease onset, dysregulation of lipid metabolism, and APP processing.

### The Intersection of Lipid Rafts, APP Processing, and AD Pathology {#S3.SS3.SSS4}

Lipid rafts are dynamic clusters of membrane lipids that interact with protein complexes to promote intracellular signal transduction ([@B297]). Normal aging is associated with gradual reductions in cholesterol and polyunsaturated fatty acids (PUFAs) in lipid rafts. With age-related changes lipid rafts composition, alterations in intracellular communication may be associated with age-associated reductions in synaptic plasticity. In neurodegenerative diseases, the composition of lipid rafts changes more rapidly, most notably in n-3 and n-6 PUFAs ([@B258]). Lipid raft aging appears to be exacerbated in Alzheimer's Disease, which may serve as the underlying contribution to disrupted signal transduction, increased APP processing, and rapid formation of AB aggregates ([@B164]). Normal APP signal transduction involves cleaving APP into AB into the extracellular environment. However, if APP interacts with ApoE and tau on a lipid raft with an atypical lipid composition, signal transduction may be disrupted, promoting the formation of AB aggregates. Other alterations include reductions in unsaturation of FA in AD patients, as compared to controls ([@B229]). Lipid raft aging also appears to exhibit gender differences, such that women had more severe changes in lipid raft composition as compared to men. This may serve as supportive evidence for the finding that postmenopausal women are more likely to progress from MCI to AD than age-matchd men (Herrera). Considering that lipid raft function is sensitive to aging, further characterization of composition changes in lipid rafts within the brain may be useful as a biomarker of neurodegenerative stages.

Lipids and Cellular Remodeling {#S3.SS4}
------------------------------

### Role of Lipid Remodeling in Synaptogenesis {#S3.SS4.SSS1}

Lipid bodies (LBs) are spherical lipid-rich organelles associated with lipid storage, metabolism, cell signaling, and inflammation ([@B373]; [@B294]). At regulated levels, LBs maintain lipid homeostasis and cellular function, but in response to brain inflammation and increased neuronal oxidative stress, these LBs grow in size and accumulate within microglial cells ([@B433]; [@B199]). Though the pathway is still largely undiscovered, LBs in microglia appear to communicate with organelles such as the mitochondria, which control cell-death mechanisms ([@B435]). When exposed to lipopolysaccharides, LBs contact to mitochondria was disrupted, but DHA treatment reduced such effects. DHA may be a key factor in preserving mitochondrial health and regulation of microglial activity ([@B433]; [@B289]). When regulated in rodent models of AD, microglia slows the accumulation of Aβ plaques, but a proliferation of microglia activity may result in brain inflammation and degradation of neuronal synapses ([@B260]; [@B408]; [@B290]). Microglial dysfunction has been implicated as a contributor to AD pathogenesis ([@B174]). Microglia cells in the brain contribute to the reorganization of neuronal circuits by phagocytosing dead neurons and their dendritic spines and axon terminals. These immune cells contribute to neural plasticity ([@B474]; [@B480]; [@B477]), which refers to the brain's ability to maintain, modify, and strengthen these synapses in order to permit neuronal communication ([@B432]).

### Importance of Lipid Remodeling/Synaptogenesis in AD Pathology {#S3.SS4.SSS2}

Synaptogenesis is the formation of nerve synapses involving the reorganization of cell structural components ([@B14]; [@B233]). Several studies suggest that presynaptic and postsynaptic development is initiated by signaling pathways involving cholesterol ([@B286]; [@B132]). Changes in fatty acid content occur prior to synaptogenesis in cones ([@B281]). Studies have shown that neurons deprived of lipid rafts underwent a cascade of effects inhibiting synaptic growth and development ([@B31]; [@B457]; [@B302]). Depletion of lipid rafts decreased dendritic density and increased the synapse, disrupting neuronal communication ([@B282]; [@B187]; [@B376]; [@B449]). The transport protein, apolipoprotein E (apoE), monitors cholesterol transport from glial cells to neurons, and impaired ApoE is implicated in deficits in synaptic plasticity and cognitive function ([@B343]). Of the three isoforms of ApoE, ApoE4 is a prevalent risk factor that is synergistic with obesity and age for AD ([@B60]; [@B361]; [@B221]; [@B331]; [@B158]). ApoE4 binds fewer lipids and is most likely involved in changes in cholesterol flux and metabolism ([@B98]; [@B440]; [@B277]; [@B325]), accounting for altered synaptogenesis and neural plasticity.

Lipids and Myelination {#S3.SS5}
----------------------

### The Importance of Myelination {#S3.SS5.SSS1}

Action potentials propagate along axons through rapid saltatory conduction. Synthesized by oligodendrocytes in the CNS and Schwann glial cells in the PNS, myelin membranes act as electrical insulators, permitting higher nerve conduction velocities and greater neuronal communication efficiency ([@B6]; [@B7]). Without myelin, axons would require more energy to depolarize its membrane ([@B410]). Myelin is composed of several lipids and protein layers that wrap around most of the axon, except at nodes of Ranvier, which are regions highly concentrated with sodium ion channels ([@B136]; [@B97]; [@B59]; [@B458]; [@B11]; [@B371]; [@B305]). Myelination of axons is a dynamic process through development and adulthood, and this process, in addition to myelin sheath modification and myelin repair, contributes to synaptic remodeling and neural plasticity ([@B488]).

### The Role of Lipids in Myelination {#S3.SS5.SSS2}

The myelin membrane consists of myelin-specific proteins and high-level synthesis of lipids representative of all major classes, such as cholesterol, glycosphingolipids, glycerophospholipids, and galactolipids ([@B85]). Lipids comprise approximately 80% of myelin's dry weight, accounting for glia's high demand for fatty acids, which are fundamental building blocks of its lipid structure ([@B109]). Myelin accounts for a majority of the white matter in the brain, which is consistent with reported reduced myelin density associated with AD white matter changes in the brain ([@B317]).

Brain Myelination and AD Pathology {#S3.SS6}
----------------------------------

Reduced number and activity of oligodendrocytes and precursor cells can damage myelin integrity, contributing to AD pathology's characteristic neuronal loss ([@B26]). Oligodendrocytes support and regulate neurons, but they are primarily responsible for myelin production ([@B393]). Myelinating oligodendrocytes are sensitive to lipid peroxidation because oxidative stress inhibits expression of genes that promote oligodendrocyte differentiation ([@B147]). This implies that disruption of myelin synthesis may be a central feature of AD pathology, and can be exploited for therapy ([@B106]). Dysfunction in these processes may be linked to white matter abnormalities and cognitive impairment associated with AD due to damaged signal conductivity and synchronicity needed for information processing between neurons ([@B206]; [@B5]; [@B317]). The causal relationship between myelination and AD has not been elucidated, but white matter changes arising from myelination dysfunctions have been described in AD brains ([@B241]). Additional evidence for the contribution of myelin breakdown on AD pathology comes from studies showing that the rate and severity of myelin breakdown in healthy seniors are associated with APOE status, a major risk factor of AD ([@B27]).

Lipids and Receptor-Mediated Signaling {#S3.SS7}
--------------------------------------

### Neuronal Receptor Signaling Pathways {#S3.SS7.SSS1}

Neurons communicate via electrochemical signals and neurotransmitters across gaps called synapses associated with several integrated networks ([@B288]; [@B250]; [@B367]; [@B170]). The presynaptic neuron releases neurotransmitters through exocytosis, and those chemicals bind to the postsynaptic neuron's neurotransmitter receptors to alter postsynaptic neuronal activity ([@B234]). One class of neurotransmitter receptors, called ligand-gated ion channel receptors, opens an ion pore through the membrane upon ligand binding. Ions cannot travel through the hydrophobic lipid membrane and, therefore, can only pass through channels controlled by these receptors. Ions entering the ligand-gated channel can initiate excitatory or inhibitory signals, but both rapidly influence neuronal function ([@B65]). Another class of neurotransmitter receptors, G-protein-coupled receptors (GPCRs), bind to the ligand and initiate an intracellular mechanism in which its G-proteins alter cAMP levels to stimulate or inhibit the neuron, and may involve lipid agonists ([@B175]). Unlike ligand-gated ion channel receptors, GPCRs are slower but longer-lasting in affecting neuronal activity ([@B271]).

### Role of Lipids in Neuronal Signaling {#S3.SS7.SSS2}

While cascades of protein kinases and phosphatases have been largely studied, there is an increasing interest in lipid-based pathways involving lipid kinases and phosphatases. Lipids are versatile in signal transduction pathways and act as hormones, ligands, substrates, and mediators ([@B127]; [@B347]; [@B346]). Sphingolipids and cholesterol comprise lipid rafts, which are regions in the plasma membrane that organize signaling molecules, amplify intracellular signaling cascades, and regulate both neurotransmission and membrane protein trafficking ([@B257]). Additionally, lipids are integral to GPCR signaling cascades. Following GPCR binding, phospholipase C (PLC) cleaves the polar phosphate head of phospholipids and forms diacylglycerol (DAG), a lipid second messenger ([@B45]). Fatty acids (FAs), especially those belonging to the omega-3 and omega-6 classes, act as ligands for membrane receptors in a variety of pathways ([@B301]). The wide diversity of lipids and their structures contributes to AD, and their multiple roles in signal transduction may influence AD pathology.

### Signaling Lipids Contribute to AD Pathology {#S3.SS7.SSS3}

Endocannabinoid signaling is responsible for inhibition and excitation in modulating synaptic strength, implicating its possible role in AD and associated inflammatory pathology ([@B397]). Although the mechanism has not been elucidated yet, free radicals and oxidative stress increase GPCR cannabinoid 2 receptors (CB2) expression in AD microglial cells, increasing neuroinflammation ([@B336]). Inflammation protects the brain against neurotoxins, but excessive inflammation may contribute to neurodegeneration. Another study suggested that monoacylglycerol lipase (MAGL) produces neuroinflammatory prostaglandins through the hydrolysis of endocannabinoids ([@B348]). Inhibiting MAGL activity is a potential AD therapeutic target because it is reported to prevent neuroinflammation, neurodegeneration, and impaired synaptic plasticity ([@B77]). Dysregulation in neuronal signaling cascades may contribute to increased susceptibility to neuronal dysfunction and are, therefore, important in studying its effects and relation to AD.

Lipids and Inflammation {#S3.SS8}
-----------------------

### The Importance of Inflammation {#S3.SS8.SSS1}

Inflammation is a defense mechanism initiated by the immune system in response to pathogens, injured cells, infections, and other toxic stimuli. A signaling cascade results in leukocyte migration to damaged sites, in which released cytokines recruit other immune cells to heal injured tissue ([@B363]). Specifically, within the CNS, activation of microglia and its associated cytokine production are primarily responsible for the inflammatory responses ([@B146]; [@B153]; [@B499]). However, unregulated inflammation, excessive cytokine production, and failure to resolve inflammatory responses all contribute to chronic neuroinflammation, a biomarker of many neurodegenerative diseases, including AD ([@B452]).

### Lipids and Inflammation {#S3.SS8.SSS2}

Several studies implicate the role of lipids and lipid metabolism in inflammatory responses ([@B215]; [@B228]; [@B489]; [@B323]). Eicosanoids are a class of lipid mediators inflammation produced by innate immune cells that contribute to acute inflammation, resulting in pain, loss of function, heat, and swelling ([@B192]; [@B463]; [@B184]; [@B438]). Following the elimination of toxic stimuli, innate immune cells cease the production of eicosanoids and begin production of specialized pro-resolving lipid mediators (SPMs) to resolve inflammation ([@B378]; [@B70]; [@B83]; [@B276]). Synthesized from omega-3 fatty acids, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), SPMs resolve inflammation by inhibiting polymorphonuclear leukocytes (PMN) and lowering vascular permeability This process may be impaired in AD ([@B462]).

### Inflammatory Lipids and AD Pathology {#S3.SS8.SSS3}

A disproportionate level of inflammation can disrupt the balance between eicosanoids and SPMs, overwhelming the brain's ability to return to a non-inflammatory state. This suggests the brain's dependence on SPMs and its omega-3 precursors, DHA, and EPA ([@B380]). AD pathology includes decreased DHA levels ([@B141]; [@B479]), which may account for heightened brain inflammation that leads to declining cognitive health. Moreover, many studies have reported alterations to the eicosanoid pathway in AD ([@B44]), further heightening research interest in the balance between eicosanoids and SPMs ([@B379]). AD is also associated with elevated microglia-induced neuroinflammation, increases in proinflammatory cytokines, and upregulated expression of phagocytic receptors in white matter microglia ([@B497]). One receptor, CD36, promotes both pro-inflammatory and oxidative pathways upon binding to ligands, including lipids and Aβ ([@B113]). Overexpression may lead to dysregulated inflammation and increased oxidative stress, a biomarker of the inflammatory response, and AD ([@B341]; [@B242]). White matter is critical to neuronal connectivity and processing speed, and such white matter inflammation may result in neurodegeneration and, therefore, the cognitive decline ([@B356]). Further studies aim to determine if inflammation contributes to the onset of AD or exacerbates already-existing neuropathology ([@B186]).

Lipids and Oxidative Stress {#S3.SS9}
---------------------------

### Oxidative Stress {#S3.SS9.SSS1}

Oxidative stress is defined as a disruption in homeostasis between antioxidants and oxidants, and more specifically, an accumulation of reactive oxidative species (ROS) and reactive nitrogen species (RNS) ([@B15]; [@B172]). ROS belongs to a family of compounds containing partially reduced oxygen species, such as O~2~-- and HO-, that are generated primarily by the electron transport chain during aerobic respiration ([@B494]). ROS are involved in many redox-dependent processes, including cell signaling, homeostasis, immune system responses, energy metabolism, and tissue remodeling. However, an excess of ROS or impaired control of the balance between antioxidants and oxidants leads to oxidative stress, which is implicated in the progression of neurodegenerative diseases ([@B74]). Because the brain consumes approximately 25% of the body's glucose, its high energy consumption increases neurons' susceptibility to oxidative stress and overproduction of ROS ([@B459]).

### Membrane Lipids Are Damaged During Oxidative Stress {#S3.SS9.SSS2}

Excess ROS can lead to increased lipid peroxidation within the brain, altering membrane permeability and activity of membrane receptors and their associated enzymes ([@B43]). Lipid peroxidation produces reactive aldehydes, including malondialdehyde (MDA) and 4-hydroxynonenal (HNE), that modify and bind to proteins involved in metabolism, antioxidant defense systems, and axonal growth. By modifying Tau protein, 4-HNE can indirectly lead to an increase in neurofibrillary tangles, which is consistent with proteomic reports of increased 4-HNE in AD hippocampal tissue and neurofibrillary tangles ([@B75]). Moreover, low-density lipid lipoprotein receptor-related protein (LRP1) is involved in Aβ peptide removal. LRP1 is oxidized by Aβ, inhibiting its ability to clear Aβ and therefore leading to Aβ accumulation in the brain ([@B388]). LRP1 is another protein that is covalently modified by 4-HNE, further supporting that unrestrained lipid peroxidation produces excess reactive products that initiate a cascade of dysregulations within pathways necessary to neuronal health ([@B61]). Oxidant/antioxidant imbalance forms blood-based biomarkers that can be used for early, non-invasive diagnosis ([@B466]), or for AD therapies ([@B481]; [@B416]).

### Oxidative Stress and AD Pathology {#S3.SS9.SSS3}

Many trials seek to assess different antioxidant therapeutic approaches to alleviate oxidative stress, a key biomarker of AD. CoQ~10~, creatine, idebenone, latrepirdine, triterpenoids, omega-3 PUFAs, vitamin E, and vitamin C are just a few antioxidants that are extensively studied in their treatment of neurodegenerative diseases ([@B481]; [@B247]).

Lipids and Immune Response {#S3.SS10}
--------------------------

### The Immune System {#S3.SS10.SSS1}

The immune system, which is divided into the innate and adaptive immune system, is critical to defending the body against infectious and toxic stimuli ([@B392]). The innate immune system utilizes cytokine production and modulation to mount a quick but sufficient response to pathogens, including viruses, bacteria, and parasites. The innate immune system is also responsible for activating the adaptive immune system, which is slower due to the lengthy production of specific antibodies to the foreign antigen ([@B213]). Studies in the past 20 years have refuted the notion of the brain as being "immunologically privileged" in relying largely on innate immune system mechanisms within the CNS. While it was thought that the CNS and immune system were separate due to the blood-brain barrier, the detection of lymphatic vessels connecting T-cells in lymph nodes to cerebrospinal fluid (CSF) in the meninges provided evidence for the brain's semi-dependence on the adaptive immune system ([@B270]). Neuroimmune processes are activated by vagal nerve signaling, immune signals, and complement proteins, resulting in increased activity of microglia and astrocytes ([@B424]).

### Lipids and Immunity {#S3.SS10.SSS2}

Studies reported increased levels of platelets and vascular lesions in AD patients outside of the brain, contributing to cerebral amyloid angiopathy, a biomarker of AD that shows increased amyloid protein in the brain arteries ([@B240]). Although platelets combat vascular injury, they are also involved in APP processing, and transitively, the formation of Aβ plaques ([@B126]; [@B125]). The balance of omega-3 and omega-6 PUFAs may affect platelet levels, as membrane essential fatty acids (EFAs), primarily DHA and EPA, form prostaglandins PGE~1~, PGE~2~, and PGE~3~, all of which participate in a variety of immunological and signaling pathways in the brain ([@B71]). PGE~1~ has anti-inflammatory properties, and conversely, PGE~2~ strongly promotes inflammation by acting on different receptors ([@B214]). PGE~3~ is responsible for regulating PGE~2~'s inflammatory effects by competing with its formation from precursor EFAs ([@B71]). Imbalances in the omega-6 to omega-3 PUFA ratios disrupt the formation of PGE~3~, which minimizes the regulation of PGE~2~ induced inflammation. Moreover, this imbalance of PUFAs is associated with changes in neuronal brain composition that, in combination with drug therapies, can reduce the risks and slow the progression of AD ([@B157]).

### Immunity and AD Pathology {#S3.SS10.SSS3}

An impaired BBB is implicated with the onset of AD, which may increase the BBB's permeability to pathogens and immune cells ([@B443]). Levels of cytotoxic and helper T-cells are upregulated in brain parenchyma of AD patients ([@B328]). Helper T cells and pro-inflammatory cytokines target neurofibrillary tangles and plaques composed of Aβ and Tau and activate microglia at these sites, further exacerbating neuroinflammation ([@B159]; [@B283]). One class of cytokines, called chemokines, stimulates leukocyte migration from blood to tissues. CCL5 is a chemokine that is amplified in response to reactive oxygen species and oxidative stress within the brain's endothelial cells, promoting even more T cell migration across the leaky BBB. These inflammatory mediators are elevated in the CSF and blood and are possible biomarkers for detecting AD and its progression ([@B299]).

Lipids and Energy Regulation {#S3.SS11}
----------------------------

### Sources of Brain Energy {#S3.SS11.SSS1}

Although the human brain comprises only 2% of the body weight, it consumes approximately 20% of glucose, demonstrating its disproportionately high energy demand ([@B295]). The majority of the energy utilized by the brain is dedicated to returning neurons to their resting states after depolarization, and the remaining 20−25% of energy is allocated toward synthesizing vesicles and neurotransmitters ([@B179]). The brain relies on a constant flow of glucose and oxygen, which are delivered through the blood. However, during fasting periods, when glucose levels are decreased, the liver can supply ketone bodies to support metabolism within the brain ([@B342]; [@B183]; [@B319]). These delivered ketone bodies are primarily utilized by astrocytes, and upon arrival, ketolysis of the ketone bodies generates acetyl CoA, an important substrate for the tricarboxylic acid (TCA) cycle and therefore, ATP production. Although the brain has a large ATP requirement, it does not utilize these ketone bodies or fatty acids as a significant source of energy like in other organs, such as the liver. It is hypothesized that evolution selected against this pathway because it produces ROS and therefore, contributes to oxidative stress that contributes to neurodegeneration ([@B374]).

### Role of Brain Energy Regulation in AD Pathology {#S3.SS11.SSS2}

Transport and utilization of glucose within the brain are tightly regulated, but mitochondrial dysfunction and decreased expression of glucose transporters (GLUT) are potential contributors to AD ([@B483]). Highly concentrated in the BBB, GLUT1 transports glucose across the endothelium and into astrocytes, whereas GLUT3 is predominantly found in axons and dendrites, underscoring its role in neuronal glucose transport and distribution ([@B442]). Reduced GLUTs expression at the BBB and within neurons is associated with AD, which may explain overall decreased glucose metabolism in AD pathology ([@B483]).

### Mitochondrial Dysfunction and AD Pathology {#S3.SS11.SSS3}

Mitochondria are organelles central to brain energy processes, and altering glucose availability or dysregulating oxidative phosphorylation can have direct effects on neuronal function and cognitive health ([@B345]; [@B10]). Recent reports have hypothesized that Aβ may initiate mitochondrial dysfunction, and one theory proposes that Aβ raises cytosolic calcium levels, inhibiting oxidative phosphorylation and, therefore, ATP production ([@B67]; [@B118]; [@B406]; [@B227]; [@B55]). Moreover, mitochondria delivery to needed brain regions is dependent on tau, a protein related to microtubules ([@B355]; [@B8]). Mitochondria are observed to be differentially localized in AD brains, suggesting that mitochondria trafficking is affected ([@B322]; [@B114]; [@B107]; [@B401]; [@B358]), and provides further support for mitochondrial-based contributors to neurodegeneration.

Potential AD Therapies Targeting Lipid Metabolism {#S4}
=================================================

Dietary Modification Studies {#S4.SS0.SSS1}
----------------------------

With the realization that lipids are altered in AD pathology, several studies have identified specific lipids that may be used as dietary supplements to alleviate AD symptoms ([Table 3](#T3){ref-type="table"}). The major lipids include omega-3 fatty acids (DHA, EPA), choline-containing lipids, cholesterol, and lipids with antioxidant properties (CoQ~10~, Vitamin K).

###### 

Lipid diets and their effects on AD.

  Lipid diet interventions                                                                                                                                                                                                                                                                                                                                                         Effects on AD
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Algal DHA^\#^; 2 g daily for 18 months                                                                                                                                                                                                                                                                                                                                           Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer's disease ([@B354]).
  Consumption of fish once or more per week                                                                                                                                                                                                                                                                                                                                        In adults above the age of 65, participants who consumed fish once or more per week had 60% less risk of developing Alzheimer's compared to participants who rarely or never ate fish ([@B310]).
  Omega-3 PUFA; 600 mg EPA and 625 mg DHA daily for 4 months                                                                                                                                                                                                                                                                                                                       In adults with mild cognitive impairment and probable AD, omega-3 supplementation had negligible effects on cognition or mood ([@B344]).
  EPA-DHA for 26 weeks; stratified into high-dose (180 mg EPA-DHA daily) and low-dose (400 mg daily)                                                                                                                                                                                                                                                                               In cognitively healthy adults over 65 years old, there were no significant differential changes in any of the cognitive domains for either low-dose or high-dose fish oil supplementation compared with placebo ([@B439]).
  Study participants are postmenopausal women (60−84 years); 1g DHA, 160 mg EPA, 240 mg Ginkgo biloba, 60 mg PS, 20 mg per day for 6 months                                                                                                                                                                                                                                        In a randomized, double-blind study, a high dose of omega-3 nutrients has cognition and mobility benefits to older women ([@B414]).
  DHA-EPA; 1.7 g DHA and 0.6 g EPA daily for 6 months (OmegAD Study)                                                                                                                                                                                                                                                                                                               Omega-3 fatty acids did not delay the rate of cognitive decline, nor did it have marked effects on neuropsychiatric symptoms except for possible positive effects on depressive symptoms in non-APOE4 carriers and agitation symptoms in APOE4 carriers ([@B150]; [@B149]). Plasma levels of AA decreased while DHA and EPA levels increased at 6 months. Specialized pro-resolving mediators (SPMs) do not change in the omega-3 group but a decrease in the placebo group. SPM changes associate with cognitive changes in AD ([@B269]).
  Omega-3 PUFAs; 1.8 g daily for 24 weeks                                                                                                                                                                                                                                                                                                                                          The omega-3 supplementation treatment group showed significant improvement in the Alzheimer's Disease Assessment Scale compared to the placebo group in participants with mild cognitive impairment. However, there was no significant improvement in Alzheimer's disease study participants ([@B82]).
  Supplementation with omega-3 fatty acids alone or omega-3 plus alpha-lipoic acid; 675 mg DHA and 975 mg EPA or 675 mg DHA and 975 mg EPA plus 600 mg lipoic acid daily for 12 months                                                                                                                                                                                             Combining omega-3 fatty acids with lipoic acid slowed both cognitive and functional decline in mild to moderately impaired AD participants over 12 months compared to placebo ([@B389]).
  3 DHA exposure variables used in separate analyses; plasma DHA, dietary DHA, and consumption of cold-water fish                                                                                                                                                                                                                                                                  Plasma and dietary DHA were associated with a decreased risk of dementia and AD ([@B269]).
  Arachidonic acid and DHA supplementation;240 mg of AA and DHA daily for 90 days                                                                                                                                                                                                                                                                                                  Participants with mild cognitive impairment showed a significant improvement in the immediate memory and attention score compared to placebo, but there was no significant improvement in participants with AD ([@B245]).
  Docosahexaenoic acid-concentrated fish oil supplementation; 430 mg of DHA and 150 mg of EPA daily for 12 months                                                                                                                                                                                                                                                                  In participants with mild cognitive impairment, supplementation resulted in a significant improvement in short-term memory, working memory, immediate verbal memory, and delayed recall capability ([@B252]).
  Fortasyn Connect supplementation; 125 mL once-a-day drink containing Fortasyn Connect for 24 months (LipiDiDiet Trial)                                                                                                                                                                                                                                                           In individuals with prodromal AD, Fortasyn Connect supplementation had no significant effect on neuropsychological test battery results ([@B400]).
  FINGER Study − Dietary intervention using a diet with 10−20% of daily energy (E%) from proteins, 25−35% from fat (less than 10E% from SAFA, 10−20% from MUFA, 5−10% from PUFA (including 2,5−3 g/day n-3 fatty acids); 45−55% from carbohydrates (less than 10% refined sugar); 25−35 g/day dietary fiber; less than 5 g/day salt; and less than 5 E% from alcohol for 2 years   In adults over 60 years old, there was a significant beneficial intervention effect on overall cognitive performance, including memory, executive function, and psychomotor speed ([@B364]).

\#

DHA, Docosahexaenoic acid (C22:6, n-3); EPA, Eicosapentaenoic acid (C20:5, n-3); MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SAFA, saturated fatty acids.

Several dietary intervention studies using DHA have yielded mixed effects on AD symptoms. A likely reason for these mixed results is that different disease severity, different formulations, and variable endpoint and time of interventions were studied ([@B138]). Recent studies indicate that the best form of DHA delivery into the brain is through the Msf2a LPC receptors ([@B415]). A better understanding of the right formulation and optimal concentrations of DHA probably supplemented at the prodromal phase of AD will likely yield beneficial outcomes.

Modification of Lipid Metabolism {#S4.SS0.SSS2}
--------------------------------

Metabolism of lipids can be altered to prevent depletion of their levels in the AD by targeting pathways that transport or catabolize these lipids in the brain.

Lipid Transport Into the Brain {#S4.SS0.SSS3}
------------------------------

Several lipoproteins and their receptor complexes are the major form by which lipids bypass the BBB to be delivered into the brain. Several of these lipoprotein genes are linked to AD pathology ([Table 1](#T1){ref-type="table"}). Some lipoproteins have protective effects, while others have AD enhancing properties. For example, HDL has been shown to be protective by improving Aβ clearance, delaying Aβ fibrillization, suppressing vascular inflammation, and inducing endothelial nitric oxide production ([@B62]).

Cholesterol Metabolism {#S4.SS0.SSS4}
----------------------

Since cholesterol metabolism altered at several stages of AD, modulation of its metabolism may have beneficial effects on disease progression. Modification of cholesterol homeostasis can be influenced during its consumption, at the level of its biosynthesis, and during its transport into the brain. The use of statin to alter cholesterol biosynthesis is proposed to be insightful in AD pathophysiology and therapy ([@B470]; [@B194]; [@B42]; [@B124]). Gene therapy targeting cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse AD models ([@B201]). Studies in mouse models show that blocking the conversion of cholesterol to cholesterol esters has beneficial effects on AD ([@B386]). The relationship between hypercholesterolemia, cholesterol-lowering therapies, and the role of oxysterols in AD pathology have led to the proposition that cholesterol metabolites are valuable targets for alternative AD treatments or prevention ([@B267]). Neuroinflammatory pathways mediated by toll-like receptor 4 (TLR4)-mediated signaling can aggravate AD symptoms. In a rodent AD model, treatment with an anti-inflammatory steroid (atorvastatin) regulates this inflammatory process and results in the amelioration of cognitive deficits ([@B451]).

Lipolytic Enzymes {#S4.SS0.SSS5}
-----------------

The activity or expression of several lipolytic enzymes are altered in AD. Phospholipase A~2~ (PLA~2~) is associated with amyloid plaques, and reduction of its activity and expression ameliorates AD. Plasmalogen selective PLA~2~ is also altered in AD. Our studies show an increase in PLA~2~ activity of CSF of AD participants accompanied by an increase in lysophosphatidylcholine (LPC). LPC is known to disrupt the BBB, and changes in PLA~2~ are associated with inflammation. The association of PLA~2~ with AD pathology suggests that inhibitors of PLA~2~ activity or expression may be an effective means of preventing AD. [@B332] reviewed the importance of several natural and synthetic PLA~2~ inhibitors on the treatment of neurological disorders. Since PLA~2~ isoforms may have divergent effects on membrane remodeling and function, there is a need for isoform-specific inhibitors in order to avoid toxicity encountered with non-selective inhibitors. In addition to PLA~2~, phospholipase D (PLD) and phospholipase C (PLC) expression and activities are associated with AD pathology. These lipases that are linked with neurite growth and signaling, respectively, offer other avenues for exploring AD treatments.

Lipid Oxidation Inhibitors {#S4.SS0.SSS6}
--------------------------

There is convincing evidence for the importance of oxidative stress on AD pathology ([@B418]; [@B28]; [@B20]). The most important brain fatty acid, DHA, is a polyunsaturated fatty that is easily susceptible to oxidative damage. While HDL is protective against oxidative damage, VLDL is easily oxidized. Oxidatively damaged lipids contribute to AD pathology by their highly neurotoxic properties ([@B29]). Approaches that reduce oxidation are expected to reduce AD progression. These include the use of natural antioxidants, carnosine, lipoic acid, Ginkgo biloba flavonoids, soybean isoflavones, vitamin K, homocysteine, curcumin ([@B365]; [@B447]; [@B145]; [@B278]; [@B491]; [@B64]). A limitation of natural antioxidant is the lack of demonstration of efficacy. Given that oxidative stress destroys mitochondrial function, an objective measure of any antioxidant can be their ability to restore mitochondrial function ([@B247]; [@B248]; [@B485]). The role of endogenous lipids in oxidative stress can be exploited when there is an uncontrolled formation of ROS and RNS or when the antioxidants contribute to disease pathology ([@B256]). Also, the source of ROS determines the effects on cellular physiology and manipulation of the ubiquinone redox state is proposed to be a viable approach of delaying aging and therapy ([@B375]; [@B466]).

Concluding Remarks {#S5}
==================

Biochemical, physiological, and genetic analyses show that lipid metabolism interphases with all the major facets of AD pathology ([Figure 1](#F1){ref-type="fig"}). In normal aging, lipid metabolic homeostasis ensures that the basic functions of the brain are met. In AD, there is dyshomeostasis of lipid metabolism, and this results in abnormal functions of the brain that characterize disease progression. This underscores the need for detailed analyses of brain lipid homeostasis in order to unravel more comprehensive mechanisms, specific biomarkers, and novel therapies of AD.
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